TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Nine-Week Versus One-Year Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 10-Year Update of the ShortHER Phase III Randomized Trial.

PierFranco Conte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.